Page 78 - Revista Argentina de Transfusión 1 - 2020
P. 78
Muchas gracias al grupo de investigacion Tarleton y a 6. Molina, I. et al. (2014) Randomized trial of posaconazole and
sus colaboradores por este duro trabajo, y especialmente benznidazole for chronic Chagas’ _disease. N. Engl. J. Med.
a Sam Kurup y Adriana Canavici por las figuras incluidas 370, 1899–1908
en este trabajo. 7. Khare, S. et al. (2015) Antitrypanosomal treatment with
benznidazole is superior to posaconazole regimens in mouse
models of Chagas disease. Antimicrob. Agents Chemother. 59,
Declaración de conflicto de intereses 6385–6394
8. Bustamante, J.M. and Tarleton, R.L. (2014) Potential new clini-
El autor ha declarado que no existe ningún conflicto cal therapies for Chagas disease. Expert Rev. Clin. Pharmacol.
de intereses. 7, 317–325
9. Bustamante, J.M. et al. (2014) New, combined, and reduced
dosing treatment protocols cure Trypanosoma cruzi infection
Fuentes in mice. J. Infect. Dis. 209, 150– _162
10. Bustamante, J.M. and Tarleton, R.L. (2011) Methodological ad-
i http://chagasfound.org vances in drug discovery for Chagas disease. Expert Opin. Drug
ii http://unitingtocombatntds.org/ Discov. 6, 653–661
iii https://clinicaltrials.gov/ 11. Bustamante, J.M. et al. (2011) Report of the 2nd Chagas Drug
Discovery Consortium meeting, held on 3 November 2010; At-
lanta GA, USA. Expert Opin. Drug Discov. 6, 965–973
Referencias 12. Peng, D. et al. (2014) CRISPR-Cas9-mediated single-gene and
gene family disruption in Trypanosoma cruzi. MBio 6, e02097–
1. Tarleton, R.L. et al. (2007) The challenges of Chagas dis- e02114
ease _grim outlook or glimmer of hope. PLoS Med. 4, 13. Tarleton, R.L. et al. (2014) Chagas disease and the London dec-
e332 laration on neglected tropical diseases. PLoS Negl. Trop. Dis.
2. Afonso, A.M. et al. (2012) A systematic review of high-quality 8, e3219
diagnostic tests for Chagas disease. PLoS Negl. Trop. Dis. 6, 14. Bustamante, J. and Tarleton, R. (2015) Reaching for the Holy
e1881 Grail: insights from infection/cure models on the prospects for
3. Tarleton, R.L. and Curran, J.W. (2012) Is Chagas disease really vaccines for Trypanosoma cruzi infection. Mem. Inst. Oswaldo
the “new HIV/AIDS of the Americas”? PLoS Negl. Trop. Dis. 6, Cruz. 110, 445–451
e1861 15. Viotti, R. et al. (2014) Towards a paradigm shift in the treat-
4. Carabarin-Lima, A. et al. (2013) Chagas disease (American ment of chronic Chagas disease. Antimicrob. Agents Chemother.
trypanosomiasis) in Mexico: an update. Acta Trop. 127, 126– 58, 635–639
135 16. Kurup, S.P. and Tarleton, R.L. (2014) The Trypanosoma cruzi
5. Gürtler, R.E. (2009) Sustainability of vector control strategies flagellum is discarded via asymmetric cell division following
in the Gran Chaco region: current challenges and possible ap- invasion and provides early targets for protective CD8+ T cells.
proaches. Mem. Inst. Oswaldo Cruz 104 (Suppl 1), 52–59 Cell Host Microbe. 16, 439–449 838 Trends
Pág. 72 AAHITC - Lavalleja 1214 (C1414DTZ) Vol. XLVI / N° 1 / 2020 Dr. Tarleton Rick L.
Cdad. Aut. de Bs. As. - Argentina Págs. 67 / 72 Traducción al español: Dra. del Pozo, Ana Emilia
Tel/Fax: (54-11)4771-2501 - L.Rot.
E-mail: aahitc@aahitc.org.ar
